Amyris Inc. (AMRSQ)
Market Cap | 1.48M |
Revenue (ttm) | 268.22M |
Net Income (ttm) | -614.55M |
Shares Out | n/a |
EPS (ttm) | -1.92 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 23,302 |
Open | 0.0020 |
Previous Close | 0.0020 |
Day's Range | 0.0020 - 0.0020 |
52-Week Range | n/a |
Beta | 1.12 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | n/a |
About AMRSQ
Amyris, Inc. operates as a biotechnology company in Europe, North America, Asia, South America, and internationally. It creates, manufactures, and commercializes consumer products and ingredient, including clean beauty, personal care, and health and wellness consumer products; and ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets. The company markets its products under the Biossance, JVN, Rose Inc., Pipette, Costa Brazil, OLIKA, Purecane, Terasana, MenoLabs, EcoFabulous, Stripe... [Read more]
Financial Performance
In 2022, Amyris's revenue was $269.85 million, a decrease of -21.06% compared to the previous year's $341.82 million. Losses were -$528.51 million, 95.4% more than in 2021.
Financial StatementsNews
Retail investors flock to penny stocks WeWork, Amyris, Proterra
WeWork, a prized startup just four years ago but now a micro-cap, and other penny stocks such as Amyris and Proterra are the latest focus of speculative bets from retail traders, with shares of the fi...
Biotech Company Amyris Files for Bankruptcy
Synthetic biotechnology company Amyris filed for Chapter 11 bankruptcy protection as it restructures, leading its share price to drop more than 70% in early trading Thursday.
AMYRIS ANNOUNCES OPERATIONAL AND FINANCIAL RESTRUCTURING TO ADVANCE STRATEGIC TRANSFORMATION
Voluntary Chapter 11 Commenced to Finalize Consensual Go-Forward Plan for Amyris' Core Business $190 Million Financing Commitment from Foris Ventures to Support Day-to-Day Operations EMERYVILLE, Calif...
Amyris Warns Of Potential Bankruptcy - Sell
Cash-strapped specialty renewable products developer Amyris remains on life support by largest shareholder and creditor John Doerr. In recent months, Doerr has provided another $157.5 million in secur...
Amyris: CEO's Exit Has Negative Implications
The resignation of Amyris' CEO is likely to be viewed as a positive by many, but the implications of this are negative. Management turnover and the engagement of a consulting firm are not signs of a h...
Amyris: Company Separates From Long-Standing CEO Amid Ongoing Restructuring Efforts - Sell
Earlier this month, cash-strapped specialty renewable products developer Amyris announced a strategic transformation program to improve the company's cost and capital structure and liquidity. Secured ...
AMYRIS ANNOUNCES CEO TRANSITION AND GLOBAL REDUCTION IN FORCE
EMERYVILLE, Calif. , June 26, 2023 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab...
AMYRIS INITIATES STRATEGIC TRANSFORMATION PROGRAM AND SECURES FUNDING
EMERYVILLE, Calif. , June 5, 2023 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-...
AMYRIS COMPLETES LICENSE FOR SUPPLY OF SUSTAINABLE SQUALENE
EMERYVILLE, Calif. , May 19, 2023 Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ techn...
Amyris, Inc. (AMRS) Q1 2023 Earnings Call Transcript
Amyris, Inc. (NASDAQ:AMRS) Q1 2023 Results Conference Call May 9, 2023 4:30 PM ET Company Participants John Melo - President and CEO Han Kieftenbeld - CFO Eduardo Alvarez - COO Conference Call Partic...
AMYRIS, INC. REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS
Core revenue of $56.1 million exceeded Q1 guidance of $49.9 million Cash operating expense down 4% compared to Q1 2022 and down 24% versus Q4 2022 Completed strategic partnership with Givaudan on Apri...
AMYRIS TO HOST FIRST QUARTER 2023 FINANCIAL RESULTS CONFERENCE CALL ON MAY 9
EMERYVILLE, Calif. , May 2, 2023 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-t...
Top 5 Materials Stocks That May Explode In May - Amyris (NASDAQ:AMRS), MP Materials (NYSE:MP)
The most oversold stocks in the materials sector presents an opportunity to buy into undervalued companies.
AMYRIS REPORTS Q1 2023 REVENUE
EMERYVILLE, Calif. , April 24, 2023 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its La...
Amyris: Sub-Scale With High Fixed Costs And Limited Growth
Amyris: Sub-Scale With High Fixed Costs And Limited Growth
AMYRIS CLOSES STRATEGIC TRANSACTION WITH GIVAUDAN
Leveraging Amyris' industry-leading biotechnology platform in Beauty for the development and supply of clean sustainable ingredients EMERYVILLE, Calif. , April 5, 2023 /PRNewswire/ -- Amyris, Inc. (Na...
Amyris, Inc. (AMRS) Q4 2022 Earnings Call Transcript
Amyris, Inc. (NASDAQ:AMRS) Q4 2022 Earnings Conference Call March 15, 2023 4:30 PM ET Company Participants Han Kieftenbeld - Chief Financial Officer John Melo - President and Chief Executive Officer ...
AMYRIS, INC. REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS
Fourth quarter Consumer revenue of $52.8 million increased 64% over the prior year and was another record quarter. Core revenue of $75.8 million grew 17% over the prior year Full year Consumer revenue...
AMYRIS TO HOST FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS CONFERENCE CALL ON MARCH 15, 2023
EMERYVILLE, Calif. , Feb. 28, 2023 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab...
GIVAUDAN TO ACQUIRE PORTFOLIO OF MAJOR COSMETIC INGREDIENTS FROM AMYRIS AND TO ESTABLISH STRATEGIC PARTNERSHIP FOR NATURAL, SUSTAINABLY SOURCED INGREDIENTS FOR THE BEAUTY INDUSTRY
The bio-based sustainable blockbuster ingredients Squalane, Hemisqualane and Cleanscreen as well as development of future cosmetic ingredients from Amyris will accelerate both companies' leadership in...
AMYRIS LAUNCHES 4U BY TIA™ HAIRCARE LINE EXCLUSIVELY AT WALMART
EMERYVILLE, Calif. , Jan. 30, 2023 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab...
Amyris: Darkest Before The Dawn
Uncertainty still surrounds the strategic transaction, but it is still likely to close in the coming weeks. Amyris' cash flow problems are improving rapidly, but a large amount of outside cash will li...
AMYRIS TO PRESENT AT THE 41st ANNUAL J.P. MORGAN HEALTH CARE CONFERENCE
EMERYVILLE, Calif. , Jan. 4, 2023 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-...
AMYRIS ANNOUNCES $50 MILLION REGISTERED DIRECT OFFERING AND CONCURRENT PRIVATE PLACEMENT
EMERYVILLE, Calif. , Dec. 29, 2022 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab...
AMYRIS SUCCESSFULLY ADVANCES STRATEGIC TRANSACTION
EMERYVILLE, Calif., Dec. 27, 2022 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-...